How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

The Phase 2/3 clinical trial design is supported by data from the Phase 1 first-in-human single ascending dose study. Presentation Information. Advertisement. ... KPL-387 is an independently developed ...

Kiniksa Pharmaceuticals, Ltd. – KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for ...

A breakthrough clinical trial in Japan reveals that a vitamin B3 derivative significantly improves symptoms of the rare ...

Discover the history, evolution, and importance of clinical trials, from James Lind's scurvy study to modern registry ...

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding ...

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.

Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic ...

The audit provides real-world performance metrics and underscores the importance of human-in-the-loop machine learning. Even advanced models require SME oversight to ensure accuracy and reliability.

THE HAGUE, Netherlands, June 3, 2025 /PRNewswire/ -- Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces the ...

One-year follow-up data from first-in-human trial shows significant improvements in key clinical performance outcomes This data supports a strong safety profile for the VCFix® Spinal System for the ...